Sigma Planning Corp Acquires New Shares in Illumina, Inc. $ILMN

Sigma Planning Corp acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, Holdings Channel.com reports. The fund acquired 7,493 shares of the life sciences company’s stock, valued at approximately $983,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in Illumina in the fourth quarter worth about $26,000. TD Waterhouse Canada Inc. purchased a new position in Illumina in the fourth quarter worth about $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter worth about $26,000. Finally, Activest Wealth Management boosted its position in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 2.6%

NASDAQ ILMN opened at $139.37 on Tuesday. The stock’s 50-day moving average price is $125.68 and its 200-day moving average price is $126.90. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 52 week low of $73.86 and a 52 week high of $155.53. The company has a market capitalization of $21.17 billion, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 2.59 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company earned $0.97 earnings per share. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts predict that Illumina, Inc. will post 5.15 earnings per share for the current year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Piper Sandler dropped their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Citigroup raised their target price on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday. Robert W. Baird set a $137.00 target price on Illumina in a research report on Friday, February 6th. Stifel Nicolaus raised their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings cut Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $131.06.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.